Weekly Digest – October 2025 Weekly Digest – October 2025 07 October 2025: ENHERTU plus Pertuzumab supplemental New Drug Application submitted in Japan as first-line therapy for patients with HER2 positive metastatic breast cancer Daiichi Sankyo has submitted a supplemental […]
Weekly Digest – October 2025 Weekly Digest – October 2025 09 October 2025: Adcendo ApS announces FDA Fast Track Designation granted to ADCE-D01 for the treatment of soft tissue sarcoma US FDA has granted Fast Track designation to Adcendo’s ADCE-D01, […]
Weekly Digest – October 2025 Weekly Digest – October 2025 09 October 2025: FDA greenlights PrimeLink Bio’s clinical trial of PLB-002 The FDA has granted IND clearance for PrimeLink Bio’s first ADC candidate, PLB-002, an anti-Claudin 6 antibody-drug conjugate, enabling […]
Weekly Digest – October 2025 Weekly Digest – October 2025 06 October 2025: DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as first-line therapy for patients with metastatic triple negative breast cancer for whom immunotherapy was not […]
Weekly Digest – October 2025 Weekly Digest – October 2025 08 October 2025: Lisata Therapeutics and Catalent announce global antibody-drug conjugate (ADC) license agreement Catalent has obtained global rights from Lisata Therapeutics to use certepetide (iRGD peptide) and its analogs […]
Weekly Digest – October 2025 Weekly Digest – October 2025 09 October 2025: Turbine launches collaboration with AstraZeneca, leveraging Turbine’s virtual disease models to rationalize ADC discovery Turbine and AstraZeneca have partnered to apply Turbine’s AI-driven virtual biology platform to […]
